A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy
Latest Information Update: 25 Sep 2024
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Trastuzumab
- Indications Carcinoma; Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms KATHERINE
- Sponsors Roche
- 25 Jul 2024 This trial has been Discontinued in Sweden, according to European Clinical Trials Database record.
- 11 Jul 2024 This trial has been Discontinued in Ireland, according to European Clinical Trials Database record.
- 14 Jun 2024 Status changed from active, no longer recruiting to completed.